Novel Treatments for Age-Related Macular Degeneration: A Review of Clinical Advances in Sustained Drug Delivery Systems
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
In recent years, the number of patients with ocular diseases is increasing as a consequence of population aging. Among them, one of the most common is the age-related macular degeneration (AMD), a condition that leads to vision loss if it is not treated. AMD is a multifactorial disorder with two advanced forms, dry and neovascular AMD. Currently, although there is no approved therapy that significantly impacts dry AMD progression, several pharmacologic therapies exist for neovascular AMD. Notwithstanding, evidence suggests a suboptimal result in a high number of patients receiving these therapeutic options. Consequently, finding effective strategies is not only a still unmet medical need in dry AMD but also in neovascular AMD. This underlines the need for new drug delivery technologies that can improve the pharmacological action and drug concentration at the target sites. In this regard, sustained drug delivery systems are presented as the most promising therapeutic options in AMD patients. This review summarized the pathogenesis and the current treatment options for AMD, focusing on the emerging ocular sustained drug delivery approaches undergoing clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AMD is one of the leading causes of irreversible visual impairment in individuals 50 years or older.4,5”
From Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“VEGF is a key mediator of the pathological angiogenesis and the formation of macular choroidal neovascularisation (CNV) that, without intervention, is directly responsible for vision loss in nAMD.2,4,5,7”
From Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Neovascular AMD (nAMD) is an advanced form of AMD, accounting for 10–20% of AMD cases and is responsible for 80–90% of severe visual loss in this disorder.5,6”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331 · cited 1×
“Age-related macular degeneration (AMD) is a disease of the retina that can progress to vision impair and even blindness in the elderly [1].”
BackgroundEffects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease
Omenn, G. S., Goodman, G. E., Thornquist, M. D., Balmes, J., Cullen, M. R., Glass, A., Keogh, J. P., Meyskens, F. L., Valanis, B., Williams, J. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605023341802 · Cited by 3,638 · cited 1×
“Nevertheless, AREDS supplementation is not recommended in smoker patients due to beta-carotene increasing the risk of lung cancer [33].”
BackgroundAge-Related Macular Degeneration and Blindness due to Neovascular Maculopathy
Ferris, F. L., Fine, S. L., & Hyman, L. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040031330019 · Cited by 1,093 · cited 1×
“Dry AMD accounts for 80–90% of cases, whereas neovascular AMD is responsible for 10–20% of AMD cases, the latter explaining the 90% of severe vision loss related to this disease [5,6].”
BackgroundLaVail, M. M., Unoki, K., Yasumura, D., Matthes, M. T., Yancopoulos, G. D., & Steinberg, R. H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.23.11249 · Cited by 719
Pharmacokinetic aspects of retinal drug delivery
del Amo, E. M., Rimpelä, A.-K., Heikkinen, E., Kari, O. K., Ramsay, E., Lajunen, T., Schmitt, M., Pelkonen, L., Bhattacharya, M., Richardson, D., et al. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.12.001 · Cited by 693
Schmidt-Erfurth, U., Chong, V., Loewenstein, A., Larsen, M., Souied, E., Schlingemann, R., Eldem, B., Monés, J., Richard, G., & Bandello, F. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305702 · Cited by 639
The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration
Fleckenstein, M., Mitchell, P., Freund, K. B., Sadda, S., Holz, F. G., Brittain, C., Henry, E. C., & Ferrara, D. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.08.038 · Cited by 561 · cited 1×
“GA presents as a gradual degeneration of retinal pigment epithelium (RPE), photoreceptors, and choriocapillaris that leads to progressive central vision loss [7,8].”
BackgroundProtection of mouse photoreceptors by survival factors in retinal degenerations.
LaVail, M. M., Yasumura, D., Matthes, M. T., Lau-Villacorta, C., Unoki, K., Sung, C. –., & Steinberg, R. H. (1998) · PubMed · Cited by 537
Research works printed but not linked: 1
- Damian, 2006, Epidemiology of age-related macular degeneration. Situation in Spain, Aten. Primaria, 38, 51
Cited by
Khanani, A. M., Boyer, D. S., Wykoff, C. C., Regillo, C. D., Busbee, B. G., Pieramici, D., Danzig, C. J., Joondeph, B. C., Major, J. C., Turpcu, A., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.102394 · Cited by 76
“2,4,5,7 Repeated intravitreal bolus injections of VEGF inhibitors (anti-VEGF) can inhibit CNV growth and leakage and stabilise or improve vision outcomes in patients with nAMD.”
BackgroundA comprehensive review of artificial intelligence models for screening major retinal diseases
Hassan, B., Raja, H., Hassan, T., Akram, M. U., Raja, H., Abd-Alrazaq, A. A., Yousefi, S., & Werghi, N. (2024) · Artificial Intelligence Review · doi:10.1007/s10462-024-10736-z · Cited by 49
Latifi‐Navid, H., Behrooz, A. B., Jamehdor, S., Davari, M., Latifinavid, M., Zolfaghari, N., Piroozmand, S., Taghizadeh, S., Bourbour, M., Shemshaki, G., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16111555 · Cited by 18
Ghosh, A. K., Nikumbh, U. S., Shukla, C. K., Laul, R. S., Dixit, A., Mahapatra, S. K., Nayak, S., Shah, U. M., Parwal, S., Narendran, V., et al. (2024) · Ophthalmology and Therapy · doi:10.1007/s40123-024-00883-5 · Cited by 9
Dual functionality of MDM2 in PROTACs expands the horizons of targeted protein degradation
Zhao, J., Chen, H., & Liang, C. (2025) · Biomarker Research · doi:10.1186/s40364-025-00826-7 · Cited by 7
Metadata
- Authors
- Jiménez-Gómez, Y., Alba-Molina, D., Blanco-Blanco, M., Pérez-Fajardo, L., Reyes-Ortega, F., Ortega-Llamas, L., Villalba-González, M., Fernández-Choquet de Isla, I., Pugliese, F., Stoikow, I., & González-Andrades, M.
- Affiliations
- Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Department of Ophthalmology, Reina Sofia University Hospital, University of Cordoba, 14004 Cordoba, Spain
- Instituto Maimónides de Investigación Biomédica de Córdoba (ES)
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-07-15
- Volume
- 14
- Issue
- 7
- Pages
- 1473
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9319243
- OpenAlex
- W4285733205
- Cited by
- 19
- References
- 71
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 5 · 2023: 3
- FWCI
- 0.33
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Instituto de Salud Carlos III, co-funded by European Union (ERDF/ESF, PAIDI2020)
- Consejería de Salud y Familias, Junta de Andalucía, co-funded by Fondo Social Europeo de Andalucía (ERDF/ESF, PAIDI2020)
- Plan Andaluz de Investigación, Desarrollo e Innovación (ERDF/ESF, PAIDI2020)
- Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía co-funded by Fondo Social Europeo de Andalucía (ERDF/ESF, PAIDI2020)
- Consejería de Salud y Familias, Junta de Andalucía (ERDF/ESF, PAIDI2020)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- age-related macular degeneration, sustained drug release, dry age-related macular degeneration, neovascular AMD, ocular drug delivery, anti-VEGF therapy, AMD pathogenesis, clinical trials, vision loss
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel Treatments for Age-Related Macular Degeneration: A Review of Clinical Advances in Sustained Drug Delivery Systems. https://app.cochat.ai/papers/10.3390/pharmaceutics14071473
- The paper
- Jiménez-Gómez, Y., Alba-Molina, D., Blanco-Blanco, M., Pérez-Fajardo, L., Reyes-Ortega, F., Ortega-Llamas, L., Villalba-González, M., Fernández-Choquet de Isla, I., Pugliese, F., Stoikow, I., & González-Andrades, M. (2022). Novel Treatments for Age-Related Macular Degeneration: A Review of Clinical Advances in Sustained Drug Delivery Systems. Pharmaceutics. https://doi.org/10.3390/pharmaceutics14071473
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.